Dream Job Opportunity ! Academic Clinical Fellowship in Haematology (Guy's, King's, UCLH and Barts available) please contact me if interested in the Guy's / Kings one. https://t.co/piHM1hGqY6
Well done to @WillVilliers and everyone involved for our new machine learning/multi-omics paper in @NatureComms.
https://t.co/6i8uPPOfAe
👇Here’s a recap:
Off to do some filming about what we can do RIGHT NOW to bring forward the day when no one dies of their blood cancer. @KingsCollegeLon & @GSTTnhs the location which is very apt given the vital role they both play in cancer discovery and treatment.
Ultra sensitive detection of FLT3-ITD: a novel and powerful MRD marker - and one that could potentially be used to guide molecularly targeted interventions. Read all about it here!
https://t.co/N16LuvoXGG
@CWLBloodDoc @Akld_DHB I think Auckland was in the top 3 recruiting centres in AML17 and also AML19 - thanks for the great, worldwide, and ongoing collaboration :-)
Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemia - Further results from the UK NCRI AML17 trial in collaboration with Australian colleagues. Hope you enjoy :-) https://t.co/W1NHj4RzKH
Had to wait for a long train ride to fully listen to this truly unmissable interview
One great quote, among many:
“The biggest tragedy is not that our drugs don’t work very well - though that’s a tragedy. The biggest tragedy is that we don’t know who they’re gonna work in.”
RECOVERY Pre-print:
In patients hospitalised with COVID-19 but no natural antibody response, monoclonal antibody infusion:
- reduced mortality
- increased speed of discharge
- reduced progression to invasive mechanical ventilation or death
https://t.co/rpDk4eUhmm
Because our supporters were determined to keep donating & fundraising through the pandemic we were able to fund £2m of new research last month including @DillonHaem's team investigating if #AML can be treated without chemotherapy.
#amazing
👇 https://t.co/U7sSys2joX